The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and ...

Robert Osher, MD, sat down with David Hutton of Ophthalmology Times to discuss the Lifetime Achievement award he received ...

The University of Arkansas for Medical Sciences (UAMS) has received a 5-year federal grant for nearly $2.2 million to study ...

The American Academy of Ophthalmology (AAO) is holding its annual meeting October 18 to 21 at McCormick Place in Chicago, ...

Corneal cross-linking (CXL) has transformed the disease course of patients with corneal ectasias since its introduction to ...

To learn more about or to register for EyeCon 2024, click here. Fort Lauderdale is the setting for EyeCon 2024, which is running from September 27 to 28, 2024. The Hilton Fort Lauderdale Marina Hotel ...

Oral gildeuretinol demonstrated a clinically meaningful reduction in the geographic atrophy lesion growth rate at 24 months, supporting additional clinical development. SAGA topline data has been ...

Sponsored Supplement: Growth Factor Supplementation: A New Paradigm in Ocular Surface Disease Management Growth factors play a crucial role in maintaining ocular surface homeostasis and health and ...

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design. These results are a part of the company’s ...

According to a team of researchers at the National Institutes of Health, their findings in animals suggest a surgery-free treatment for cataracts. Researchers at the National Institutes of Health (NIH ...

Ripple will lead preclinical development of RTC-620 while AbbVie will lead the clinical and commercialization activities upon exercise of option-to-license agreement. Ripple Therapeutics has announced ...